Effects of combined ethanol extract of Anthocleista vogelii and Alstonia boonei stem barks on sex hormonal levels of benign prostatic hyperplasia (BPH) induced rats
محورهای موضوعی : مجله گیاهان داروییرابرت اوروکو 1 , چوکو چارلز نانا 2 , جوسفات اکور 3 , داوید اباسی 4 , نیکیو ازوگو 5
1 - گروه بیوشیمی ، کالج علوم طبیعی ، دانشگاه کشاورزی مایکل اوکپارا ، امودایکه ، ایالت ابیا ، نیجریه.
2 - گروه بیوشیمی ، کالج علوم طبیعی ، دانشگاه کشاورزی مایکل اوکپارا ، امودایکه ، ایالت ابیا ، نیجریه.
3 - واحد آزمایشگاهی ، گروه بیوشیمی ، دانشکده علوم طبیعی ، دانشگاه کشاورزی مایکل اوکپرا ، امودایکه ، ایالت ابیا ، نیجریه
4 - گروه بیوشیمی ، دانشگاه اوانگل ، آکائزه ، ایالت ابونی ، نیجریه.
5 - گروه بیوشیمی ، کالج علوم طبیعی ، دانشگاه کشاورزی مایکل اوکپارا ، امودایکه ، ایالت ابیا ، نیجریه.
کلید واژه: estradiol, androgenic hormones, Alstonia boonei, Anthocleista vogelii, benign prostatic, hyperplasia, prostate weight,
چکیده مقاله :
Background & Aim:Combined ethanol extract of A. vogelii and A. boonei stem (CEAA) barks is commonly used to treat prostate disorders whereas its effects on benign prostatic hyperplasia (BPH) has not been scientifically validated. This study investigated the effects of CEAA on prostate weight, prostate index and serum androgenic and estrogenic hormonal levels of BPH induced rats.Experimental: The study had 6 groups containing 5 male Wistar albino rats each. Group 1 was the normal control rats without BPH induction while group 2 was the BPH induced rats without any treatment (BPH) control. Groups 3 – 5 were BPH induced rats treated with 5 mg/kg finasteride/day, 200 and 400 mg/kg CEAA/day, respectively. BPH was induced in groups 2 – 5 by the subcutaneous administration of testosterone propionate injection in olive oil for 28 consecutive days.Results: The BPH control indicated significantly (p <0.05) increases in prostate weight, prostate index, serum testosterone (TT), dihydrotestosterone (DHT) and estradiol (E2) concentrations relative to the normal control. Treatment with CEAA caused dose-dependent significant (p <0.05) decreases in the prostate weight, prostate index, TT, DHT and E2 similar to finasteride-treated BPH induced rats when compared with BPH control rats. The CEAA had high inhibitory effects on the prostate weight (55.71 -82.86 %) and prostate index (65.33 – 86.52 %) of the BPH induced rats greater than 71.52 % and 81.63 % inhibition of prostate weight and prostate index by finasteride, respectively.Recommended applications/industries: The findings of this study indicated that combined ethanol extract of A. vogelii and A. boonei stem barks has anti-benign prostatic hyperplasia activities as it down-regulated the serum concentrations of TT, DHT and E2 implicated in BPH development and progression
Background & Aim:Combined ethanol extract of A. vogelii and A. boonei stem (CEAA) barks is commonly used to treat prostate disorders whereas its effects on benign prostatic hyperplasia (BPH) has not been scientifically validated. This study investigated the effects of CEAA on prostate weight, prostate index and serum androgenic and estrogenic hormonal levels of BPH induced rats.Experimental: The study had 6 groups containing 5 male Wistar albino rats each. Group 1 was the normal control rats without BPH induction while group 2 was the BPH induced rats without any treatment (BPH) control. Groups 3 – 5 were BPH induced rats treated with 5 mg/kg finasteride/day, 200 and 400 mg/kg CEAA/day, respectively. BPH was induced in groups 2 – 5 by the subcutaneous administration of testosterone propionate injection in olive oil for 28 consecutive days. Results: The BPH control indicated significantly (p < 0.05) increases in prostate weight, prostate index, serum testosterone (TT), dihydrotestosterone (DHT) and estradiol (E2) concentrations relative to the normal control. Treatment with CEAA caused dose-dependent significant (p < 0.05) decreases in the prostate weight, prostate index, TT, DHT and E2 similar to finasteride-treated BPH induced rats when compared with BPH control rats. The CEAA had high inhibitory effects on the prostate weight (55.71 -82.86 %) and prostate index (65.33 – 86.52 %) of the BPH induced rats greater than 71.52 % and 81.63 % inhibition of prostate weight and prostate index by finasteride, respectively. Recommended applications/industries: The findings of this study indicated that combined ethanol extract of A. vogelii and A. boonei stem barks has anti-benign prostatic hyperplasia activities as it down-regulated the serum concentrations of TT, DHT and E2 implicated in BPH development and progression
Aggarwal, S., Thareja, S., Verma, A., Bhardwaj, T.R. and Kumar, M. 2010. An overview of 5α-reductase inhibitors. Steroids, 75(2): 109–153.
Alaribe, C.S.A., Corker H.A.B, Shode, F.O., Ayoola, G., Adesegun, S.A., Bamiro, J., Anyim, E.I. and Anyakora, C. 2011. Antiplasmodial and phytochemical investigation of leaf extract of Anthocleista vogelii. Journal of Natural Products, 5: 60–67.
Alshawsh, M.A., Mothana, R.A., AlShamahy, H.A., Alsllami, S.F. and Lindequist, U. 2009. Assessment of antimalarial activity against Plasmodium falciparum and phytochemical screening of some Yemeni medicinal plants. Evidence-Based Complementary and Alternative, 6: 453–456.
Babu, S.V., Veeresh, B., Patil, A.A. and Warke, Y.B. 2020. Lauric acid and myristic acid prevent testosterone-induced prostatic hyperplasia in rats. European Journal of Pharmacology, 626(2-3): 262-265.
Bisson, J.F., Hidalgo, S., Rozan, P. and Messaoudi, M. 2007. The therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract, on experimentally induced prostate hyperplasia in Wistar-Unilever rats. Journal of Medicinal Food, 10(4): 628-635.
Carson, C. and Rittmaster, R. 2003. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61(4): 2-7.
Chapelle, J.P. 1976. Vogeloside et acide secologanique, glucosides seco-iridoids d' Anthocleista vogelii. Planta Medica, 29: 268–274.
Fakae, B.B., Campbell, A.M., Barrett, J., Scott,I.M., Teesdale-Spittle, P.H., Liebau, E., and Brophy, P.M. 2000. Inhibition of glutathione S-transferases (GSTs) from parasitic nematodes by extracts from traditional Nigerian medicinal plants. Phytotherapy Research, 14(8):630–634.
Gacci, M., Eardley, I., Giuliano, F., Hatzichristou, D., Kaplan, S.A., Maggi, M. and Roehrborn, C.G. 2011. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology, 60(4): 809-825.
Gasco, M., Villegas. L., Yucra. S., Rubio, J. and Gonzales, G.F. 2007. Dose-response effect of red maca (Lepidium meyenii) on benign prostatic hyperplasia induced by testosterone enanthate. Phytomedicine, 14(7-8): 460-464.
Grant, P. and Ramasamy, S. 2012. An update on plant-derived anti-androgens. International Journal of Endocrinology and Metabolism, 10(2): 497–502.
Hadi, S. and Bremner, J.B. 2001. Initial studies on alkaloids from Lombok medicinal plants. Molecules, 6(2):117–129
Hongcai, C., Guowei, Z., Zechen, Y. and Xuejun, S. 2018. The effect of Xialiqi capsule on testosterone-induced benign prostatic hyperplasia in rats. Evidence-Based Complementary and Alternative, 2018: 1-9
Imperato-McGinley, J., Walsh, P.C., McConnell, J.D. and Vaughan, E.D. 1992. The effect of finasteride in men with benign prostatic hyperplasia. The New England Journal of Medicine, 327(17): 1185-1191.
Institute of Laboratory Animal Resources 1986. Committee on Care, Use of Laboratory Animals. Guide for the care and use of laboratory animals (No. 86). US Department of Health and Human Services, Public Health Service, National Institutes of Health.
Irwin, D.E., Milsom, I., Kopp, Z., Abrams, P., Artibani, W. and Herschorn, S. 2009. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. European Urology, 56(1):14-20.
Jang, H., Ha, U.S., Kim, S.J., Yoon, B., Han, D., Yuk, S. and Kim, S.W. 2010. Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. Journal of Agricultural and Food Chemistry, 58(24):12686-12691.
Jiofack, T., Fokunang, C., Guedje, N., Kemeuze, V., Fongnzossie, E., Nkongmeneck, B.A., Mapongmetsem, P.M. and Tsabang, N. 2010. Ethnobotanical uses of medicinal plants of two ethnoecological regions of Cameroon. International Journal of Medical Sciences, 2: 60-79.
Lorke, D. 1983. A new approach to practical acute toxicity testing. Archives of Toxicology, 54(4): 275-287.
McConnell, J.D., Roehrborn, C.G., Bautista, O.M., Dixon, C.M., Kusek, J.W., Lepor, H., McVary, K.T., Nyberg, K.T., Leroy, M., Harry S. C., Crawford, E.D., Diokno., Diokno, A., Foley, J.P., Foster., H.E., VS.C., KaplanS.A., Kreder, K.J., Lieber, M.M., Lucia., M.S., Miller, G.J., Menon, M., Milam, D.F., Ramsdell, J.W., Schenkman, N.S., Slawin, K.M. and Smith, J.A. 2003. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England Journal of Medicine, 349(25): 2387-2398.
McPherson, J.S., Hussaina, S., Balanathana, P., Hedwards, S.L., Niranjan, B., Grant, M., Chandrasiri, U.P., Toivanen, R., Wang, Y., Taylor, R.A. and Risbridger, G.P. 2010. Estrogen receptor-activated apoptosis in benign hyperplasia and cancer of the prostate is androgen-independent and TNF mediated. Proceedings of the National Academy of Sciences, 107(7): 3123–3128.
Mizokami, A., Koh. E., Izumi, K., Narimoto., K., Takeda, M., Honma S., Dai, J., Keller , E.T., and Namiki, M. 2009. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through a synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocrine-Related Cancer, 16(4): 1139–1155.
Musa, A.D., Yusuf, G.O., Ojogbane, E.B. and Nwodo, O.F.C. 2010. Screening of eight plants used in folkloric medicine for the treatment of typhoid fever. Journal of Chemical and Pharmaceutical Research, 2(4): 7-15.
Okon, E.O., Gboeloh, L.B. and Udoh, S.E. 2014. Antimalarial effect of combined extracts of the leaf of Ficus exasperata and stem bark of Anthocleista vogelii on mice experimentally infected with plasmodium Berghei berghei (Nk 65). Research Journal of Medicinal Plants, 8: 99-111.
Osadebe, P.O. 2002. Anti-inflammatory properties of the root bark of A. boonei. Nigerian Journal of Natural Products and Medicine, 6: 39–41.
Pais, P. 2020. Potency of a novel saw palmetto extract, SPET-085, for inhibition of 5 alpha-reductase II. Advances in Therapy, 27: 555-563.
Parsons, J.K. and Kashefi, C. 2008. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. European Urology, 53(6): 1228-1235.
Sasagawa, I., Nakada, T., Kazama, T., Satomi, S., Terada, T. and Katayama, T. 1990. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy. International Urology and Nephrology, 22: 279–284.
Schatzl, G., Brössner, C., Schmid, S., Kugler, W., Roehrich, M., Treu, T., Szalay, A., Djavan, B., Schmidbauer, C.P., Söregi, S. and Madersbacher, S. 2000. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology, 55: 397–402.
Shinde, J.S., Khurde, S.S., Suchita, S.L., Chavan, S.S. and Hulmajge, S.B. 2016. Need of polyherbal formulations and its standardization: A Review. World Journal of Pharmaceutical Sciences, 5(11): 526-533.
Steers, W.D. 2001. 5 alpha-reductase activity in the prostate. Urology, 58 (1 Suppl, 6): 17–24.
Tepongning, R.N., Lucantoni, L., Nasuti, C.C., Dori, G.U., Yerbanga, S.R., Lupidi, G., Marini, C., Rossi, G., Esposito, F., Habluetzel, A. 2011.Potential of a Khaya ivorensis-Alstonia boonei extract combination as antimalarial prophylactic remedy. Journal of Ethnopharmacology, 137: 743-751.
Tietz, N.W.1995. Clinical Guide to Laboratory Tests, 3rd edition, W.B Sanders Co, Philadelphia. Pp. 578-580.
Traish, A.M., Hassani, J., Guay, A.T., Zitzmann, M. and Hansen, M.L. 2011. Adverse side effects of 5α‐reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Journal of Sexual Medicine, 8(3): 872–884.
Tsurusaki, T., Aoki, D., Kanetake, H., Inoue, S., Muramatsu, M., Hishikawa, Y. and Koji, T. 2003. Zone-dependent expression of estrogen receptors and in human benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism, 88(3):1333–1340.
